# Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

> **NCT01757405** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 40 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **BIOLOGICAL:** Recombinant Factor VIIa BI (rFVIIa BI)
- **BIOLOGICAL:** Recombinant Factor VIIa BI (rFVIIa BI)

## Key facts

- **NCT ID:** NCT01757405
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-20
- **Primary completion:** 2014-11-11
- **Final completion:** 2014-11-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757405, "Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01757405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*